Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Esquivel-Moynelo
  RPCEC00000307		 RCTIFN gammastandard of careCOVID 19 hospitalizedhigh
41/38 suggested
  • suggested 2.3-fold increase in viral clearance ,viral clearance (time to event analysis only) (PE) but with a low degree of certainty due to high risk of bias
  • suggested 2.1-fold increase in viral clearance by day 7 but with a low degree of certainty due to high risk of bias
SOLIDARITY (interferon)
  NCT04315948		 RCTIFN beta-1acontrolCOVID 19 hospitalizedsome concern
2063/2064 inconclusive
  • inconclusive 16 % increase in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias

COVID-19 mild to moderate meta-analysis

Fu
  ChiCTR2000030262		 RCTinterferon / TFF2standard of careCOVID-19 mild to moderatesome concern
40/40 conclusif
    Jagannathan
          NCT04331899    		 RCTpeginterferonplaceboCOVID-19 mild to moderatesome concern
    		60/60 inconclusive

      COVID-19 severe or critically meta-analysis

      Darazam (COVIFERON Interferon beta-1a)
              NCT04343768      		 RCTinterferonstandard of careCOVID-19 severe or criticallysome concern
      		20/20 suggested
      • suggested 1.4-fold increase in clinical improvement,clinical improvement (time to event analysis only) with a moderate degree of certainty due to some concern in risk of bias
      Darazam (COVIFERON Interferon beta-1b)
              NCT04343768      		 RCTIFN beta-1bstandard of careCOVID-19 severe or criticallysome concern
      		20/20 inconclusive
        Kalil (ACTT-3)
                  NCT04492475        		 RCTIFN beta-1aplaceboCOVID-19 severe or criticallysome concern
        		487/482 inconclusive
        • inconclusive 1 % decrease in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
        Davoudi-Monfared
                  IRCT20100228003449N2        		 RCTIFN beta-1astandard of careCOVID-19 severe or criticallyhigh
        		46/46 suggested
        • suggested 70 % decrease in death D28 but with a low degree of certainty due to high risk of bias
        • suggested 63 % decrease in deaths,deaths (time to event analysis only) but with a low degree of certainty due to high risk of bias
        • inconclusive 10 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) but with a low degree of certainty due to high risk of bias
        Rahmani
                  IRCT20100228003449N2        		 RCTIFN beta-1bstandard of careCOVID-19 severe or criticallysome concern
        		40/40 conclusif
        • demonstrated 2.4-fold increase in clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
        2 studies excluded by filtering options (0 RCT / 2 OBS)

        PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
        Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

         

        - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons